POLISCOPE
Back to feed
NewsBreitbartMay 3, 2026United States

Federal Appeals Court Blocks Mail-Order Abortion Pill Access

A federal appeals court has halted a 2023 FDA rule that allowed the abortion medication mifepristone to be prescribed via telehealth and sent through the mail. The court ruled that the state of Louisiana is likely to succeed in its lawsuit challenging the FDA's decision-making process, citing concerns over safety data and state sovereignty.

abortionmifepristoneFDAcourt rulinghealthcare regulation
Read the full story at Breitbart

Why It Matters

This ruling temporarily prevents the distribution of mifepristone by mail nationwide while the underlying lawsuit proceeds, directly impacting how patients in states with abortion restrictions access the medication.

Key Facts

  • The Fifth Circuit Court of Appeals issued an injunction blocking the FDA's 2023 rule that allowed mifepristone to be dispensed by mail.
  • The court ruled that Louisiana has legal standing to sue the FDA over the mail-order policy.
  • The court found that the FDA's 2023 decision to remove in-person dispensing requirements was likely 'arbitrary and capricious' under the Administrative Procedure Act.
  • The ruling claims the FDA relied on inadequate safety data and eliminated reporting requirements for adverse events, then used the lack of data to justify the rule change.
  • The court rejected arguments from drug manufacturers Danco Laboratories and GenBioPro that the stay would cause irreparable financial harm.
  • The ruling is a reversal of a lower district court decision that had declined to block the regulation in April.
  • Drug manufacturers have filed emergency motions with the U.S. Supreme Court to stay the appeals court's ruling.
  • The FDA originally approved mifepristone in 2000 with strict in-person requirements, which were gradually relaxed in 2016, 2021, and 2023.

Who's Mentioned

otherKyle DuncanotherU.S. Food and Drug Administration (FDA)organizationDanco Laboratories“Manufacturer of mifepristone that intervened in the case.”otherDanco LaboratoriesorganizationGenBioPro“Manufacturer of mifepristone that intervened in the case.”personKurt Engelhardt“Circuit Judge on the panel.”otherU.S. Court of Appeal for the Fifth CircuitotherKurt EngelhardtotherGenBioProotherBiden administrationpersonKyle Duncan“Circuit Judge who wrote the court's opinion.”otherDonald TrumpotherGeorge W. BushotherLeslie SouthwickpersonLiz Murrill“Louisiana Attorney General.”otherLouisianapersonLeslie Southwick“Circuit Judge on the panel.”organizationU.S. Food and Drug Administration“The federal agency that issued the 2023 rule allowing mail-order mifepristone.”otherSupreme CourtorganizationU.S. Court of Appeals for the Fifth Circuit“The court that issued the ruling blocking the FDA rule.”locationLouisiana“The state that filed the lawsuit against the FDA.”personRosalie Markezich“Plaintiff in the lawsuit.”otherRosalie Markezich